These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12655447)

  • 1. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
    Kiani A; Köhne CH; Franz T; Passauer J; Haufe T; Gross P; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):266-70. PubMed ID: 12655447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
    Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
    Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
    Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
    Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
    Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
    Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
    Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
    J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
    Masumori N; Kunishima Y; Hirobe M; Takeuchi M; Takayanagi A; Tsukamoto T; Itoh T
    Jpn J Clin Oncol; 2008 Mar; 38(3):182-5. PubMed ID: 18270381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
    Shamseddine AI; Khalifeh MJ; Mourad FH; Chehal AA; Al-Kutoubi A; Abbas J; Habbal MZ; Malaeb LA; Bikhazi AB
    Clin Pharmacokinet; 2005; 44(9):957-67. PubMed ID: 16122282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
    Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
    Freise KJ; Martín-Jiménez T
    J Vet Pharmacol Ther; 2006 Apr; 29(2):147-52. PubMed ID: 16515669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.
    Koolen SL; Huitema AD; Jansen RS; van Voorthuizen T; Beijnen JH; Smit WM; Schellens JH
    Oncologist; 2009 Sep; 14(9):944-8. PubMed ID: 19726456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
    Kuemmerle A; Decosterd LA; Buclin T; Liénard D; Stupp R; Chassot PG; Mosimann F; Lejeune F
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):331-41. PubMed ID: 18587581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
    Veerman G; Ruiz van Haperen VW; Vermorken JB; Noordhuis P; Braakhuis BJ; Pinedo HM; Peters GJ
    Cancer Chemother Pharmacol; 1996; 38(4):335-42. PubMed ID: 8674156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
    Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
    Serdjebi C; Gattacceca F; Seitz JF; Fein F; Gagnière J; François E; Abakar-Mahamat A; Deplanque G; Rachid M; Lacarelle B; Ciccolini J; Dahan L
    Ther Drug Monit; 2017 Jun; 39(3):290-296. PubMed ID: 28346313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
    Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
    J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
    Ramón-López A; Escudero-Ortiz V; Duart-Duart MJ; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(4):194-206. PubMed ID: 22078546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
    Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
    Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
    Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
    Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.